Cynthia Collins
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Certara analysts raise price targets, maintain positive outlook. TD Cowen kept its buy rating on Certara and lifted its price target to $11. Barclays also maintained an equal‑weight stance and increased its target to $9. A Yahoo analysis noted the company's fair‑value estimate moving higher as the turnaround gains traction. The upgrades suggest growing confidence among analysts.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Transaction History
| MXCT | ▲ Buy | Grant | 30,421 | $0 | 6/17/2026 | View on chart |
| CERT | ▲ Buy | Option Exercise | 15,757 | $0 | 5/14/2026 | View on chart |
| MXCT | ▲ Buy | Grant | 29,210 | $0 | 6/18/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 40,983 | $0 | 6/10/2025 | View on chart |
| CERT | ▲ Buy | Option Exercise | 11,928 | $0 | 5/21/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 71,174 | $0 | 3/28/2025 | View on chart |
| MXCT | ▲ Buy | Grant | 51,679 | $0 | 10/14/2024 | View on chart |
| CERT | ▲ Buy | Option Exercise | 8,663 | $0 | 5/21/2024 | View on chart |
| CERT | ▲ Buy | Option Exercise | 9,067 | $0 | 5/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer
MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.